gynaecological cancer, pelvic cancer
Conditions
Interventions
We are investigating the added value of quantitative MRI. In particular, we are measuring perfusion and diffusion properties of tissue. The MRI sequences include: 
Intra-voxel incoherent motion diffusion-weighted MRIDynamic contrast-enhanced MRIT2* relaxometrie
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: All adult patients (18 years or older) with pelvic cancer who are possibly eligible for curative radiotherapy with or without hyperthermia - 18 years or older - histologically confirmed primary pelvic tumour, - possibly eligible for primary radiotherapy (with or without chemotherapy and/or hyperthermia) - able to understand and read Dutch or English, - written informed consent (Dutch or English)
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - all who do not comply to the inclusion criteria - those with a contra-indication for MRI (i.e. MRI incompatible metal implants, pacemaker, severe claustrophobia) - those with a contra-indication for MRI-contrast agent (i.e. known allergic reaction, poor functioning of the kidneys eGFR
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end-point is to show feasibility of perfusion MRI by determining significant changes in blood circulation in HT and RT patients. Furthermore, several secondary end-points aim at using the data for hypothesis generating and retrieving the essential preliminary data to allow for designing more in depth studies into using perfusion MRI as biomarker for HT efficacy. | — |
Secondary
| Measure | Time frame |
|---|---|
| See above. | — |
Countries
Netherlands
Contacts
Public ContactL. J. A. Stalpers
Amsterdam UMC
Outcome results
None listed